IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

DELIVERED AT THE 21ST WHO EXPERT COMMITTEE ON THE SELECTION AND USE OF ESSENTIAL MEDICINES

ifpma | March 27, 2017

news image

Thank you for the opportunity to make this statement today on behalf of the research-based pharmaceutical companies and associations across the globe. It seems appropriate that today....

Read More

EBE, EFPIA AND IFPMA HAVE TODAY LAUNCHED A POSITION PAPER ENTITLED “CONSIDERATIONS FOR PHYSICIANS ON SWITCHING DECISIONS REGARDING BIOSIMILARS”.

ifpma | March 09, 2017

news image

Switching describes a physician’s decision to exchange one product that a patient receives for another. With the introduction of biosimilars, physicians may be encouraged to switch patients from an original biologic (reference product) to any of its biosimilars (or vice versa) in order to reduce costs....

Read More

IFPMA LAUNCHES NEW POLICY PRINCIPLES AND REPORT ON RARE DISEASE DAY 2017 TO BENEFIT PATIENTS, HEALTHCARE AND SOCIETY

ifpma | February 28, 2017

news image

Celebrating Rare Disease Day 2017, IFPMA launches today new resources to help increase understanding and awareness of rare diseases. These include a set of policy principles outlining critical elements for a global framework on rare disease policy and a report that describes key challenges in areas such as R&D, clinical trials, diagnosis, and access to treatment....

Read More

G-FINDER REPORT 2016: THE BIOPHARMACEUTICAL INDUSTRY CONFIRMS ITS STATUS AS A SIGNIFICANT FUNDER OF NEGLECTED DISEASE R&D

ifpma | February 16, 2017

news image

IFPMA, the international association representing the innovative biopharmaceutical industry, welcomes the G-FINDER 2016[1] results, which shows that industry consolidated its status as a main funder of neglected disease R&D in 2015....

Read More
news image

DELIVERED AT THE 21ST WHO EXPERT COMMITTEE ON THE SELECTION AND USE OF ESSENTIAL MEDICINES

ifpma | March 27, 2017

Thank you for the opportunity to make this statement today on behalf of the research-based pharmaceutical companies and associations across the globe. It seems appropriate that today....

Read More
news image

EBE, EFPIA AND IFPMA HAVE TODAY LAUNCHED A POSITION PAPER ENTITLED “CONSIDERATIONS FOR PHYSICIANS ON SWITCHING DECISIONS REGARDING BIOSIMILARS”.

ifpma | March 09, 2017

Switching describes a physician’s decision to exchange one product that a patient receives for another. With the introduction of biosimilars, physicians may be encouraged to switch patients from an original biologic (reference product) to any of its biosimilars (or vice versa) in order to reduce costs....

Read More
news image

IFPMA LAUNCHES NEW POLICY PRINCIPLES AND REPORT ON RARE DISEASE DAY 2017 TO BENEFIT PATIENTS, HEALTHCARE AND SOCIETY

ifpma | February 28, 2017

Celebrating Rare Disease Day 2017, IFPMA launches today new resources to help increase understanding and awareness of rare diseases. These include a set of policy principles outlining critical elements for a global framework on rare disease policy and a report that describes key challenges in areas such as R&D, clinical trials, diagnosis, and access to treatment....

Read More
news image

G-FINDER REPORT 2016: THE BIOPHARMACEUTICAL INDUSTRY CONFIRMS ITS STATUS AS A SIGNIFICANT FUNDER OF NEGLECTED DISEASE R&D

ifpma | February 16, 2017

IFPMA, the international association representing the innovative biopharmaceutical industry, welcomes the G-FINDER 2016[1] results, which shows that industry consolidated its status as a main funder of neglected disease R&D in 2015....

Read More